Upstream Bio Shares Slide After Mixed Phase 2 VALIANT Results for Verekitug
Upstream Bio's stock dropped 23% after the company released mixed results from its Phase 2 VALIANT study of verekitug for severe asthma. Both tested dosing schedules achieved statistically significant reductions in annualized asthma exacerbation rate (AAER), but the 100mg every 12 weeks dosing produced a larger reduction and was judged more compara…